A Study of Oral LY317615 in Relapsed or Refractory Diffuse Large B-Cell Lymphomas.
Back to Top
Basic Trial Information
Trial Description
Summary
Eligibility Criteria
Trial Contact Information
| Phase | Type | Status | Age | Sponsor | Protocol IDs |
|---|---|---|---|---|---|
| Phase II | Treatment | Completed | 18 and over | Pharmaceutical / Industry | 4849 H6Q-MC-JCAI, UCLA-0210010, LILLY-H6Q-MC-JCA, CWRU-080213J, LILY-1402, UNMC-18502, NCT00042666 |
Summary
This study will measure the effectiveness and any side effects of LY317615 in patients with Diffuse large B-cell lymphoma (a sub-type of Non-Hodgkins Lymphoma).
Eligibility Criteria
Inclusion Criteria:
- A diagnosis of recurrent or refractory Diffuse B-cell Non-Hodgkin's lymphoma.
- Adequate organ functions.
- Able to swallow capsules.
Exclusion Criteria:
- More than 3 prior treatments for this disease.
- Serious heart problems.
Trial Lead Organizations/Sponsors
Eli Lilly and Company
| Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern Time (UTC/GMT - 5 hours, EST) |  | Study Director |
Link to the current ClinicalTrials.gov record.
NLM Identifer NCT00042666
Information obtained from ClinicalTrials.gov on December 14, 2011
Note: Information about this trial is from the ClinicalTrials.gov database. The versions designated for health professionals and patients contain
the same text. Minor
changes may be made to the ClinicalTrials.gov record to standardize the names of study sponsors, sites, and
contacts. Cancer.gov only lists sites that are recruiting patients for active trials, whereas ClinicalTrials.gov lists all sites for all trials. Questions and comments regarding the presented information should
be directed to ClinicalTrials.gov.
Back to Top
